The Rationale for the Effectiveness of Applying Radiopharmaceuticals Based on ~(177)Lu for Radionuclide Therapy

摘要

Using WinAct and IDAC-dose 2.1, dose coefficients for organs and tumor were calculated for monoclonal antibodies rituximab, tetulomab, cetuximab and 7E11 with different radionuclides. The results were received based on distribution radiopharmaceutical in nude mice. Using the method of Sparks and Aydogan, cumulated activity was recalculated for humans. The ratio of the dose coefficient on the tumor to the organ shows that lutetium-177 is more favourable for radionuclide therapy since the dose per tumor is much greater than the dose per organ in comparison to other radionuclides.